Molecular Partners (MOLN) Expected to Announce Quarterly Earnings on Thursday

Molecular Partners (NASDAQ:MOLN) is anticipated to post its Q3 2025 results after the market closes on Thursday, October 30th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 3:00 AM ET.

Molecular Partners (NASDAQ:MOLN) last issued its quarterly earnings results on Monday, August 25th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.14). On average, analysts expect Molecular Partners to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Molecular Partners Price Performance

Shares of NASDAQ:MOLN opened at $3.61 on Tuesday. Molecular Partners has a 1 year low of $3.36 and a 1 year high of $6.63. The stock has a market capitalization of $145.73 million, a price-to-earnings ratio of -1.74 and a beta of 1.09. The company’s 50 day simple moving average is $3.73 and its 200 day simple moving average is $3.77.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on MOLN. JPMorgan Chase & Co. lowered their price target on Molecular Partners from $4.50 to $4.00 and set a “neutral” rating for the company in a report on Wednesday, September 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Molecular Partners in a research note on Tuesday, October 14th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Molecular Partners presently has an average rating of “Hold” and a consensus target price of $8.00.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.